As the United Kingdom’s FTSE 100 index grapples with the ripple effects of weak trade data from China, investors are keenly observing how these global cues impact domestic markets. In such a climate, identifying promising small-cap stocks that demonstrate resilience and potential for growth becomes crucial, particularly those less exposed to international volatility and more aligned with stable local demand.
Name
Debt To Equity
Revenue Growth
Earnings Growth
Health Rating
B.P. Marsh & Partners
NA
38.21%
41.39%
★★★★★★
BioPharma Credit
NA
7.22%
7.91%
★★★★★★
Bioventix
NA
7.39%
5.15%
★★★★★★
Rights and Issues Investment Trust
NA
-7.87%
-8.41%
★★★★★★
Andrews Sykes Group
NA
2.08%
5.03%
★★★★★★
Nationwide Building Society
277.32%
10.61%
23.42%
★★★★★☆
Goodwin
37.02%
9.75%
15.68%
★★★★★☆
FW Thorpe
2.95%
11.79%
13.49%
★★★★★☆
Distribution Finance Capital Holdings
9.15%
50.88%
67.63%
★★★★★☆
AltynGold
73.21%
26.90%
31.85%
★★★★☆☆
Let’s explore several standout options from the results in the screener.
Simply Wall St Value Rating: ★★★★★☆
Overview: Mha Plc provides financial and business strategy services to enterprises and individuals, with a market cap of £367.49 million.
Operations: Revenue from Mha Plc’s provision of professional services stands at £154.04 million.
Mha, a dynamic player in the UK market, has shown impressive growth with earnings surging 28% over the past year, outpacing the Professional Services industry’s -2.8%. The company trades at 18.5% below its estimated fair value and boasts high-quality earnings. Recent guidance indicates a significant revenue increase to £224 million for FY25, marking a 45.4% rise from £154 million in FY24. Despite concerns about future earnings decline averaging 31.2% annually over three years, Mha’s robust cash position relative to debt and strong interest coverage paint a promising picture for potential investors seeking undervalued opportunities.
AIM:MHA Debt to Equity as at Jul 2025
Simply Wall St Value Rating: ★★★★★★
Overview: BioPharma Credit PLC is an investment trust focused on investing in interest-bearing debt assets, with a market cap of approximately $987.03 million.
Operations: The investment trust generates revenue primarily from its investments in debt assets secured by royalties, amounting to $150.03 million. With a market cap of approximately $987.03 million, the company’s financial focus is on leveraging interest-bearing debt assets for income generation.
Story Continues
BioPharma Credit stands out in the UK market with its robust financial health and strategic positioning. The company, debt-free for five years, showcases high-quality earnings and a significant 12.7% growth in earnings over the past year, outpacing the Capital Markets industry average of 7.4%. Its shares are trading at a notable 22.2% discount to estimated fair value, suggesting potential upside for investors. Recent events include an interim dividend declaration of $0.0175 per share, reinforcing shareholder value commitment. With levered free cash flow reaching $140 million as of June 2024, BioPharma Credit seems well-positioned for continued stability and growth potential in its niche sector.
LSE:BPCR Debt to Equity as at Jul 2025
Simply Wall St Value Rating: ★★★★☆☆
Overview: Metro Bank Holdings PLC is a bank holding company for Metro Bank PLC, offering business, commercial, retail and private banking products and services in the United Kingdom with a market cap of £881.60 million.
Operations: Metro Bank Holdings generates revenue primarily from its banking segment, totaling £398.20 million. The company’s net profit margin is a key financial metric to consider when evaluating its profitability.
Metro Bank Holdings, with total assets of £17.6 billion and equity of £1.2 billion, has been navigating a challenging landscape. The bank’s earnings grew by 44% last year, outpacing the industry average of 11.9%, despite a significant one-off loss of £75 million affecting recent results. Total deposits stand at £14.9 billion against loans totaling £9 billion, but concerns arise from the high level of bad loans at 5.5% and a low allowance for bad loans at 38%. With most liabilities funded by customer deposits (91%), Metro Bank remains focused on strategic growth through higher-yielding loan products and digital partnerships like Infosys to enhance operational efficiency while managing risks in corporate lending exposure.
LSE:MTRO Earnings and Revenue Growth as at Jul 2025
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include AIM:MHA LSE:BPCR and LSE:MTRO.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com